• Billstrom, R., Johansson, B., Fioretos, T., Garwicz, S., Malm, C., Zettervall, O. & Mitelman, F. (1997) Poor survival in t(8;21) (q22;q22)-associated acute myeloid leukaemia with leukocytosis. European Journal of Haematology, 59, 4752.
  • Byrd, J.C., Dodge, R.K., Carroll, A., Baer, M.R., Edwards, C., Stamberg, J., Qumsiyeh, M., Moore, J.O., Mayer, R.J., Davey, F., Schiffer, C.A. & Bloomfield, C.D. (1999) Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. Journal of Clinical Oncology, 17, 37673775.
  • Gramatzki, M., Ludwig, W.D., Burger, R., Moos, P., Rohwer, P., Grunert, C., Sendler, A., Kalden, J.R., Andreesen, R., Henschke, F. & Moldenhauer, G. (1998) Antibodies TC-12 (‘‘unique’’) and TH-111 (CD96) characterize T-cell acute lymphoblastic leukemia and a subgroup of acute myeloid leukemia. Experimental Hematology, 26, 12091214.
  • Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A. & Goldstone, A. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood, 92, 23222333.
  • Illmer, T., Schuler, U.S., Thiede, C., Schwarz, U.I., Kim, R.B., Gotthard, S., Freund, D., Schakel, U., Ehninger, G. & Schaich, M. (2002) MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Research, 62, 49554962.
  • Leblanc, T. & Berger, R. (1997) Molecular cytogenetics of childhood acute myelogenous leukaemias. European Journal of Haematology, 59, 113.
  • Nguyen, S., Leblanc, T., Fenaux, P., Witz, F., Blaise, D., Pigneux, A., Thomas, X., Rigal-Huguet, F., Lioure, B., Auvrignon, A., Fiere, D., Reiffers, J., Castaigne, S., Leverger, G., Harousseau, J.L., Socie, G. & Dombret, H. (2002) A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood, 99, 35173523.
  • Pearson, L., Leith, C.P., Duncan, M.H., Chen, I.M., McConnell, T., Trinkaus, K., Foucar, K. & Willman, C.L. (1996) Multidrug resistance-1 (MDR1) expression and functional dye/drug efflux is highly correlated with the t(8;21) chromosomal translocation in pediatric acute myeloid leukemia. Leukemia, 10, 12741282.
  • Raspadori, D., Damiani, D., Lenoci, M., Rondelli, D., Testoni, N., Nardi, G., Sestigiani, C., Mariotti, C., Birtolo, S., Tozzi, M. & Lauria, F. (2001) CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia, 15, 11611164.
  • Schaich, M., Ritter, M., Illmer, T., Lisske, P., Thiede, C., Schakel, U., Mohr, B., Ehninger, G. & Neubauer, A. (2001) Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia. British Journal of Haematology, 112, 300307.
  • Schaich, M., Harbich-Brutscher, E., Pascheberg, U., Mohr, B., Soucek, S., Ehninger, G. & Illmer, T. (2002) Association of specific cytogenetic aberrations with mdr1 gene expression in adult myeloid leukemia and its implication in treatment outcome. Haematologica, 87, 455464.